Fungal infection treatment in Kochi,
on the IADVL ITART / INTACT consensus, KOH-confirmed first.

Chronic recurrent dermatophytosis in India is most often due to terbinafine-resistant Trichophyton indotineae, a newly-recognised drug-resistant dermatophyte species that originated in India in the mid-2010s and is now the dominant cause of chronic recalcitrant cases in Indian practice. Resistance is driven by SQLE gene point mutations. Standard empirical terbinafine 250 mg/day repeatedly fails, the protocol must be culture-guided with itraconazole or voriconazole alternatives. DermaVue Kochi performs culture + sensitivity BEFORE prescribing in any chronic/recurrent case.

T. indotineae is a newly-recognised dermatophyte species (genotype VIII of the T. mentagrophytes/interdigitale complex) that originated in the Indian subcontinent and has spread globally, with imported cases now reported in the UK, Ontario, Europe, and the USA. The clinical picture: extensive, inflammatory tinea corporis/cruris/faciei lesions, often steroid-misuse-modified, failing repeated terbinafine courses, recurring within weeks of apparent clearance. India is the global epicentre of this epidemic.

Topical corticosteroids (particularly clobetasol, sold OTC in India under many brand names) appear to improve fungal infections initially because they suppress the inflammatory response and reduce itching. But they suppress local immune function which allows the dermatophyte to spread silently, and on withdrawal the infection rebounds worse than before, often as 'tinea incognito' (atypical presentation). Steroid-cream discontinuation is the non-negotiable first step in any fungal infection treatment at DermaVue Kochi.

Terbinafine 250 mg/day is the traditional first-line oral antifungal for dermatophytosis, but Indian T. indotineae shows high-level resistance to it. Itraconazole 200 mg/day is the evidence-supported alternative for resistant cases, extended to 12-24 weeks for chronic recalcitrant infections. Itraconazole requires monthly LFT monitoring (hepatotoxicity risk) and has more drug interactions than terbinafine. The choice is culture-guided at DermaVue, empirical prescription in chronic/recurrent cases wastes patient time and money.

Standard acute case (terbinafine-susceptible): 4-6 weeks oral + topical. Chronic recalcitrant or T. indotineae confirmed: itraconazole 200 mg/day for 8-24 weeks. Multi-azole-resistant cases: voriconazole 6-12 weeks. Recurrence prevention requires steroid-cream avoidance + household contact treatment + occlusion control (loose breathable clothing, prompt drying after bath/sweat). Re-examination + repeat KOH at 4 weeks confirms treatment response.

Yes, dermatophytosis is highly transmissible through shared towels, clothing, bedding, and personal contact. Household contact screening + treatment of any affected family member is built into DermaVue's protocol. Treating only the index patient while household contacts remain infected guarantees re-infection within weeks. The standard recommendation: any household member with similar lesions or itching gets concurrent treatment + shared items (towels, bedsheets) replaced or hot-washed.

Kochi's sustained 85-95% RH is documented as creating optimal growth conditions for dermatophytes, but climate is not modifiable. What IS modifiable: prompt drying after bath / pool / sweat-heavy exercise; loose cotton clothing (avoid synthetic occlusive fabrics in groin / underarm / foot zones); shared-item hygiene (own towels and clothing); steroid-cream avoidance; and once-infected, completing the full course of treatment plus household screening. Prevention is largely about behaviour modification, not climate avoidance.

₹300 consultation. KOH microscopy ₹200-400. Fungal culture + sensitivity ₹800-2,500. Topical antifungal ₹400-1,200/month. Oral itraconazole ₹450-1,200/month. Voriconazole (when needed for multi-azole-resistant cases) ₹3,500-12,000 for a 2-week course. Monthly LFT during itraconazole ₹400-800. Total typical chronic-case 12-week programme: ₹6,000-15,000. Cheaper than the cumulative cost of repeated failed terbinafine courses elsewhere.

Because India is the global epicentre of T. indotineae terbinafine resistance, and empirical prescription without species identification leads to repeated treatment failures, patient frustration, increased resistance pressure, and household transmission. Culture-guided therapy is the evidence-supported approach (IADVL India + IJDVL position). The ₹800-2,500 culture cost is meaningfully less than the cumulative cost (in money, time, and treatment failure morbidity) of empirical cycling.

Untreated or repeatedly-flaring chronic dermatophytosis can cause post-inflammatory hyperpigmentation (PIH, particularly visible in Fitzpatrick IV-VI skin), lichenification (thickened leathery skin from chronic scratching), nail dystrophy (if onychomycosis), and rarely secondary bacterial infection. Most damage is reversible with proper culture-guided treatment + PIH-fading topicals (azelaic acid 15-20%) post-clearance. Permanent scarring is uncommon unless complicated by deep abscess formation.